|Videos|September 11, 2020

Standard of Care in Patients With Heart Failure

Episodes in this series

EP. 1 Pathophysiology of Different Types of Heart Failure

EP. 2 Progressive Nature and Associated Risks of Diabetes on HF

EP. 3 Cost and Utilization Profile for a Patient With HF

EP. 4 Economic Burden of Heart Failure and Goals of Treatment

Now Playing

EP. 5 Standard of Care in Patients With Heart Failure

EP. 6 Reducing Readmissions Due to Heart Failure

EP. 7 CV Outcomes Studies With Medications Indicated for Diabetes

EP. 8 Recent Studies of SGLT-2s in Patients with HFrEF

EP. 9 Implications of Using SGLT2 Inhibitors With HFpEF and HFrEF

EP. 10 SGLT2 Inhibitors in Patients Without Diabetes at Risk of HF

EP. 11 SGLT2 Inhibitors as Standard of Care Throughout Cardiology

EP. 12 Guidelines Regarding Use of SGLT2s for Patients With Diabetes and HF

EP. 13 Quantifying Potential Impact of SGLT2 Inhibitors for HF

EP. 14 Systemic Change to Support Care of Patients With HF

EP. 15 Treatment of Patients With Heart Failure

EP. 16 Interest Regarding Diabetes and CVD Risk

EP. 17 Takeaways of DAPA-HF: SGLT2s for CVD

EP. 18 Using SGLT2 Inhibitors to Achieve Cardiovascular Benefits

EP. 19 Cost-Effectiveness of SGLT2s for CVD

Cardiologists review the current pharmacologic treatment options and evaluate hospitalization rates across use of traditional heart failure medications.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges

Surrogate End Points, Drug Costs Complicate Oncology Formularies

Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote

Perceptions About CGMs Among Primary Care Physicians and Endocrinologists

COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD

Building a Cellular Therapy Program in the Community Oncology Setting: Perspectives and Lessons Learned